GREENLAND MINES LTD Total Liabilities and Equity
GREENLAND MINES LTD (GRML) had Total Liabilities and Equity of $65.01 million as of 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-17
- 2026-06-30: Liabilities and Equity $65.01M.
- 2026-03-31: Liabilities and Equity $59.74M.
- 2025-12-31: Liabilities and Equity $9.59M.
- 2025-09-30: Liabilities and Equity $10.07M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $65.01M 10-Q · filed 2026-08-17 | |
| 2026-03-31 | $59.74M 10-Q/A · filed 2026-08-14 | |
| 2025-12-31 | $9.59M 10-Q · filed 2026-08-17 | |
| 2025-09-30 | $10.07M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $10.85M 10-Q · filed 2025-08-18 | |
| 2025-03-31 | $2.99M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $2.46M 10-K/A · filed 2026-08-14 | |
| 2024-09-30 | $2.46M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $3.31M 10-Q · filed 2024-08-19 | |
| 2024-03-31 | $19.59M 10-Q · filed 2024-05-23 | |
| 2023-12-31 | $2.19M 10-K · filed 2025-03-31 | $19.46M 10-K · filed 2024-04-17 |
| 2023-09-30 | $58.02M 10-Q · filed 2023-11-17 | |
| 2023-06-30 | $57.21M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $119.76M 10-Q · filed 2023-05-24 | |
| 2022-12-31 | $118.25M 10-K · filed 2024-04-17 | |
| 2022-09-30 | $117.16M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $116.96M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $256.93K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $4.95K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |